IA
ENTA icon

IFP Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

IFP Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5K Hold
396
– – ﹤0.01% 3528
2025
Q4 		$6.25K Hold
396
– – ﹤0.01% 3307
2025
Q3 		$4.74K Buy
396
+11
+3% +$88 ﹤0.01% 3286
2025
Q2 		$3.08K Buy
+385
New +$2.32K ﹤0.01% 3683
2025
Q1 		– Sell
-3
Closed -$17 – 4402
2024
Q4 		$17 Buy
+3
New +$29 ﹤0.01% 4475
2020
Q4 		– Sell
-259
Closed -$11.4K – 2987
2020
Q3 		$11K Buy
+259
New +$12.5K ﹤0.01% 1864
2018
Q4 		– Sell
-136
Closed -$12K – 3615
2018
Q3 		$12K Hold
136
– – ﹤0.01% 2739
2018
Q2 		$16K Hold
136
– – ﹤0.01% 2597
2018
Q1 		$8K Hold
136
– – ﹤0.01% 2912
2017
Q4 		$8K Hold
136
– – ﹤0.01% 2957
2017
Q3 		$6K Hold
136
– – ﹤0.01% 3291
2017
Q2 		$5K Hold
136
– – ﹤0.01% 3383
2017
Q1 		$4K Sell
136
-175
-56% -$5.45K ﹤0.01% 3400
2016
Q4 		$10K Buy
311
+136
+78% +$3.9K ﹤0.01% 2889
2016
Q3 		$5K Sell
175
-1,476
-89% -$34.3K ﹤0.01% 3215
2016
Q2 		$36K Buy
+1,651
New +$43.2K ﹤0.01% 1966
2016
Q1 		– Sell
-1,714
Closed -$57K – 2654
2015
Q4 		$57K Buy
+1,714
New +$55.9K ﹤0.01% 1524

Other funds holding ENTA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
SSC
Spruce Street Capital New York $416M AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IFP Advisors's ENTA Position: Q1 2026 in Review

IFP Advisors held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 396 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #3528.

IFP Advisors first reported a position in ENTA in Q4 2015 and has held it in 17 quarters since. The position peaked at $57K in Q4 2015. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

  • IFP Advisors held 396 shares of Enanta Pharmaceuticals worth $5K as of Q1 2026.
  • IFP Advisors left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
  • Enanta Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q1 2026, its #3528 holding.
  • IFP Advisors first reported a position in Enanta Pharmaceuticals in Q4 2015 and has held it in 17 quarters since.
  • IFP Advisors's Enanta Pharmaceuticals position peaked at $57K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on IFP Advisors's 13F filing for Q1 2026, filed 13 Apr 2026.